The data indicate that PD1-Fc-OX40L is able to bind PD-L1 and OX40 simultaneously, stimulate OX40 signaling in the absence of cross-linking, and provide improved control of tumor immunity as compared to combinations of PD1 and OX40 targeted antibodies. The gene discussed is TNFSF4; the disease is neoplasm.